At a glance
ClinicalIndex Comparison RecordN/ACompleted· 53 enrolled
Drug / intervention
5-ALA-SFC +1 moredrug
Likely dose
5-ALA-SFC 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Subjects With Type II Diabetes
In Brief
A clinical study evaluating 5-ALA-SFC and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 53 participants.
Detailed Summary
The aim of this pilot study is to assess the safety and preliminary efficacy of 5-ALA - SFC at doses up to 200 mg per day in subjects with type II diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
Countries--
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJul 2014
First PostedJun 2015
Primary CompletionJul 2015
TodayJul 2026
First PostedJun 25, 2015
Enrollment StartJul 1, 2014
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 11.0 years ago
Interventions
5-ALA-SFCdrug
Study product will be in the form of white-opaque capsules for oral administration, containing either 50, 75, or 100 mg of active 5-ALA - SFC
Placebodrug